ModernGraham Valuation

Company Name:

Company Ticker MYL Date of Analysis Mylan N.V.



Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

3/25/2017

Defensive Investor; must pass 6 out of the following 7 tests.

1.	Adequate Size of the Enterprise	Market Cap > \$2Bil	\$22,279,352,200	Pass
2.	Sufficiently Strong Financial Condition	Current Ratio > 2	1.49	Fail
3.	Earnings Stability	Positive EPS for 10 years prior		Fail
4.	Dividend Record	Dividend Payments for 10 years prior		Fail
5.	Earnings Growth	Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end	-11200.00%	Fail
6.	Moderate PEmg Ratio	PEmg < 20	15.06	Pass
7.	Moderate Price to Assets	PB Ratio < 2.5 OR PB*PEmg < 50	1.92	Pass

Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.

 Sufficiently Strong Financial Condition 	Current Ratio > 1.5	1.49 Fail
2. Sufficiently Strong Financial Condition	Debt to NCA < 1.1	6.13 Fail
3. Earnings Stability	Positive EPS for 5 years prior	Pass
4. Dividend Record	Currently Pays Dividend	Fail
5. Earnings Growth	EPSmg greater than 5 years ago	Pass
	Score	

Suitability

Defensive	No
Enterprising	No

Stage 2: Determination of Intrinsic Value

	EPSmg		\$2.72
	MG Growth Estimate		15.00%
	MG Value		\$104.69
	MG Value based on 3% Growth		\$39.43
	MG Value based on 0% Growth		\$23.11
	Market Implied Growth Rate		3.28%
MG Opinion			
	Current Price		\$40.96
	% of Intrinsic Value		39.12%
	Opinion	Undervalued	
	MG Grade	C+	

Stage 3: Information for Further Research


Net Current Asset Value (NCAV)	-\$30.91
Graham Number	\$49.05
PEmg	15.06
Current Ratio	1.49
PB Ratio	1.92
Current Dividend	\$0.00
Dividend Yield	0.00%
Number of Consecutive Years of Dividend	
Growth	0

Useful Links:

ModernGraham tagged articles Google Finance Yahoo Finance GuruFocus Morningstar MSN Money Seeking Alpha SEC Filings

EPS History		EPSmg History	
Next Fiscal Year			
Estimate	+	Next Fiscal Year Estimate	\$2.72
Dec2016	\$0.92	Dec2016	\$1.54
Dec2015	\$1.70	Dec2015	\$1.79
Dec2014	\$2.34	Dec2014	\$1.71
Dec2013	\$1.58	Dec2013	\$1.29
Dec2012	\$1.52	Dec2012	\$0.94
Dec2011	\$1.22	Dec2011	\$0.57
Dec2010	\$0.68	Dec2010	\$0.28
Dec2009	\$0.30	Dec2009	\$0.17
Dec2008	-\$1.05	Dec2008	\$0.25
Mar2007	\$0.99	Mar2007	\$0.91
Mar2006	\$0.79	Mar2006	\$0.89
Mar2005	\$0.74	Mar2005	\$0.89
Mar2004	\$1.21	Mar2004	\$0.89
Mar2003	\$0.96	Mar2003	\$0.68
Mar2002	\$0.91	Mar2002	\$0.52
Mar2001	\$0.13	Mar2001	\$0.33
Mar2000	\$0.52	Balance Sheet Information	12/1/2016
Mar1999	\$0.41	Total Current Assets	\$7,522,500,000
Mar1998	\$0.36	Total Current Liabilities	\$5,040,700,000
Mar1997	\$0.23	Long-Term Debt	\$15,202,900,000
		Total Assets	\$34,726,200,000
		Intangible Assets	\$23,679,700,000
		Total Liabilities	\$23,610,000,000
		Shares Outstanding (Diluted Average)	520,500,000





Disclaimer:

This valuation is not investment advice. Anyone who is considering making an investment decision should speak to a registered investment advisor.

The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing those holdings within the next 72 hours.

Recommended Reading:

 Other
 Mylan NV Valuation – January 2016 Update \$MYL

 ModernGraham posts about the company
 32 Companies in the Spotlight This Week – 12/6/14 Mylan Inc. Annual Valuation – 2014 \$MYL

 Other ModernGraham posts about related companies
 Amgen Inc Valuation – March 2017 \$AMGN Celgene Corporation Valuation – March 2017 \$CELG Ligand Pharmaceuticals Inc Valuation – Initial Coverage \$LGND Pfizer Inc Valuation – March 2017 \$PFE Supernus Pharmaceuticals Inc Valuation – Initial Coverage \$SUPN Lannett Company Inc Valuation – Initial Coverage \$LCI Spectrum Pharmaceuticals Inc Valuation – Initial Coverage \$SPPI Abbott Laboratories Valuation – January 2017 \$ABT Johnson & Johnson Valuation – January 2017 \$JNJ Allergan plc Valuation – January 2017 \$AGN